Myriad Genetics
MYGN
252 hedge funds and large institutions have $3.31B invested in Myriad Genetics in 2015 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 93 increasing their positions, 90 reducing their positions, and 50 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
3% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 90
2% more capital invested
Capital invested by funds: $3.25B → $3.31B (+$63.8M)
8% less funds holding
Funds holding: 273 → 252 (-21)
18% less call options, than puts
Call options by funds: $22.1M | Put options by funds: $26.9M
36% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$58.5M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$51.3M |
| 3 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
+$19M |
| 4 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$17.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$60.1M |
| 2 |
Tiger Global Management
New York
|
-$57.6M |
| 3 |
NTC
North Tide Capital
Boston,
Massachusetts
|
-$37.5M |
| 4 |
SCM
Snow Capital Management
Sewickley,
Pennsylvania
|
-$28.2M |
| 5 |
GAM
Gotham Asset Management
New York
|
-$19.4M |
MYGN Hedge Fund Activity: Q1 2015 in Review
252 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2015, worth a combined $3.31B — up 2% from $3.25B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of MYGN and 32 opened new positions — a net loss of 18 holders — while 90 trimmed existing stakes and 93 added.
The largest buyer was Scopia Capital Management, adding an estimated $58.5M. The largest seller was Royce & Associates, cutting an estimated $60.1M.
- 252 institutional investors held Myriad Genetics (MYGN) as of Q1 2015, down from 273 in Q4 2014.
- Funds reported $3.31B of Myriad Genetics stock for Q1 2015, up 2% quarter-over-quarter.
- 32 funds opened new Myriad Genetics positions in Q1 2015 and 50 closed out, a net change of -18 holders.
- The largest Myriad Genetics buyer in Q1 2015 was Scopia Capital Management, an estimated $58.5M added.
- The largest Myriad Genetics seller in Q1 2015 was Royce & Associates, an estimated $60.1M sold.
Based on aggregated 13F filings for Q1 2015.